Apellis Pharmaceuticals - Stock Price History | APLS

Historical daily share price chart and data for Apellis Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Apellis Pharmaceuticals as of September 24, 2021 is 31.40.
  • The all-time high Apellis Pharmaceuticals stock closing price was 69.84 on July 02, 2021.
  • The Apellis Pharmaceuticals 52-week high stock price is 73.00, which is 132.5% above the current share price.
  • The Apellis Pharmaceuticals 52-week low stock price is 27.50, which is 12.4% below the current share price.
  • The average Apellis Pharmaceuticals stock price for the last 52 weeks is 49.37.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Apellis Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 34.9557 31.1650 57.2000 17.9100 57.2000 86.81%
2019 22.9126 13.6200 32.1800 12.8100 30.6200 132.15%
2018 19.1255 20.7800 30.0000 11.4700 13.1900 -39.22%
2017 14.7214 14.0300 21.7000 12.7100 21.7000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.820B $0.251B
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Apellis Pharmaceuticals, Inc. is based in CRESTWOOD, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71